|1.||Lees, Kennedy R: 6 articles (01/2006 - 10/2003)|
|2.||GAIN International Steering Committee and Investigators: 4 articles (09/2004 - 10/2003)|
|3.||Lees, K R: 4 articles (01/2004 - 02/2000)|
|4.||Weir, Christopher J: 3 articles (09/2004 - 10/2003)|
|5.||Aslanyan, Stella: 3 articles (09/2004 - 10/2003)|
|6.||Barnaby, R J: 3 articles (04/2003 - 02/2000)|
|7.||Chiu, David: 2 articles (05/2010 - 01/2006)|
|8.||Kaste, M: 2 articles (01/2004 - 06/2000)|
|9.||Kajbaf, M: 2 articles (04/2003 - 09/2000)|
|10.||Diener, H C: 2 articles (01/2001 - 06/2000)|
05/01/2005 - "Both trials reported that gavestinel was ineffective in ischemic stroke. "
01/01/2004 - "While planning the GAIN International Study of gavestinel in acute stroke, a sequential triangular test was proposed but not implemented. "
01/01/2004 - "How a sequential design would have affected the GAIN International Study of gavestinel in stroke."
11/01/2001 - "Gavestinel produces no benefit for stroke patients, study finds."
04/04/2001 - "In this study, gavestinel administered up to 6 hours after an acute ischemic stroke did not improve functional outcome at 3 months."
|2.||Brain Ischemia (Cerebral Ischemia)
05/11/2001 - "GV150526 was administered at a dose of 3 mg/kg i.v. T2-weighted (T2W) and diffusion weighted (DW) images were acquired at 6, 24 and 144 h after the establishment of the cerebral ischemia. "
02/01/2000 - "GV150526, a selective glycine site antagonist, reduces infarct volume in rats with focal cerebral ischemia. "
09/09/1999 - "Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia."
10/08/1997 - "The nanomolar potency of GV 150526A in reducing NMDA receptor function by competitively acting at the strychnine-insensitive glycine sites suggests that GV 150526A could be effective in vivo to reduce NMDA receptor over-stimulation, like in brain ischemia."
05/01/2005 - "These observations from the combined GAIN International and GAIN Americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage. "
05/01/2005 - "The primary hypothesis was that gavestinel treatment did not alter outcome, measured at 3 months by the Barthel Index (BI), from acute intracerebral hemorrhage, based on pooled results from both trials. "
05/01/2005 - "Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies."
|5.||Brain Injuries (Brain Injury)
10/01/2002 - "Glutamate N-methyl-D-aspartate (NMDA) receptor antagonists (competitive receptor antagonists, ion channel blockers, and glycine antagonists)--such as selfotel, aptiganel, eliprodil, licostinel and gavestinel--failed to show efficacy in clinical trials of stroke or traumatic brain injury. "
|1.||Glycine (Aminoacetic Acid)
|10.||Glutamic Acid (Glutamate)